These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38630755)

  • 21. Comparison of ASCL1, NEUROD1, and POU2F3 expression in surgically resected specimens, paired tissue microarrays, and lymph node metastases in small cell lung carcinoma.
    Handa T; Hayashi T; Ura A; Watanabe I; Takamochi K; Onagi H; Kishi M; Matsumoto N; Tajima K; Kishikawa S; Saito T; Takahashi K; Suzuki K; Yao T
    Histopathology; 2023 May; 82(6):860-869. PubMed ID: 36715573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC).
    Ding XL; Su YG; Yu L; Bai ZL; Bai XH; Chen XZ; Yang X; Zhao R; He JX; Wang YY
    World J Surg Oncol; 2022 Feb; 20(1):54. PubMed ID: 35220975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessing treatment outcomes of chemoimmunotherapy in extensive-stage small cell lung cancer: an integrated clinical and radiomics approach.
    Zhao J; He Y; Yang X; Tian P; Zeng L; Huang K; Zhao J; Zhou J; Zhu Y; Wang Q; Chen M; Li W; Gao Y; Zhang Y; Xia Y
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy.
    Shirasawa M; Yoshida T; Shiraishi K; Takigami A; Takayanagi D; Imabayashi T; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yotsukura M; Yoshida Y; Nakagawa K; Tsuchida T; Hamamoto R; Yamamoto N; Motoi N; Kohno T; Watanabe SI; Ohe Y
    Lung Cancer; 2023 May; 179():107183. PubMed ID: 37037178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In-depth proteomic analysis reveals unique subtype-specific signatures in human small-cell lung cancer.
    Szeitz B; Megyesfalvi Z; Woldmar N; Valkó Z; Schwendenwein A; Bárány N; Paku S; László V; Kiss H; Bugyik E; Lang C; Szász AM; Pizzatti L; Bogos K; Hoda MA; Hoetzenecker K; Marko-Varga G; Horvatovich P; Döme B; Schelch K; Rezeli M
    Clin Transl Med; 2022 Sep; 12(9):e1060. PubMed ID: 36149789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular Subtypes of High-Grade Neuroendocrine Carcinoma (HGNEC): What is YAP1-Positive HGNEC?
    Kawai H; Matsuoka R; Ito T; Matsubara D
    Front Biosci (Landmark Ed); 2022 Mar; 27(3):108. PubMed ID: 35345340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The expression of YAP1 and other transcription factors contributes to lineage plasticity in combined small cell lung carcinoma.
    Jimbo N; Ohbayashi C; Fujii T; Takeda M; Mitsui S; Tanaka Y; Itoh T; Maniwa Y
    J Pathol Clin Res; 2024 Sep; 10(5):e70001. PubMed ID: 39283755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.
    Ragavan M; Das M
    Curr Treat Options Oncol; 2020 Jun; 21(8):64. PubMed ID: 32601742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer.
    Kelenis DP; Rodarte KE; Kollipara RK; Pozo K; Choudhuri SP; Spainhower KB; Wait SJ; Stastny V; Oliver TG; Johnson JE
    Cancer Res; 2022 Sep; 82(17):3058-3073. PubMed ID: 35748745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Whole-Section Landscape Analysis of Molecular Subtypes in Curatively Resected Small Cell Lung Cancer: Clinicopathologic Features and Prognostic Significance.
    Hwang S; Hong TH; Kim HK; Choi YS; Zo JI; Shim YM; Han J; Chan Ahn Y; Pyo H; Noh JM; Lee HY; Kim HJ; Park S; Ahn MJ; Park K; Lee SH; Choi YL; Kim J
    Mod Pathol; 2023 Jul; 36(7):100184. PubMed ID: 37054974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic Implications of Small Cell Lung Cancer Transcriptional Subtyping for CNS Metastases.
    Tringale KR; Skakodub A; Egger J; Eichholz J; Yu Y; Gomez D; Rimner A; Li B; Yamada Y; Wilcox J; Moss N; Imber BS; Rekhtman N; Baine MK; Rudin CM; Pike LRG
    JCO Precis Oncol; 2024 Apr; 8():e2300470. PubMed ID: 38691815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
    Tenjin Y; Kudoh S; Kubota S; Yamada T; Matsuo A; Sato Y; Ichimura T; Kohrogi H; Sashida G; Sakagami T; Ito T
    Lab Invest; 2019 Nov; 99(11):1622-1635. PubMed ID: 31231131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peripheral NK cells identified as the predictor of response in extensive-stage small cell lung cancer patients treated with first-line immunotherapy plus chemotherapy.
    Cui Y; Chen Y; Zhao P; Li S; Cheng Y; Ren X
    Clin Transl Oncol; 2024 Oct; 26(10):2522-2530. PubMed ID: 38662170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcomes and synergistic effect between radiotherapy and immunotherapy in patients with extensive-stage small cell lung cancer: a real-world study.
    Sun M; Ji H; Deng F; Li J; Xu N; Li Y
    BMC Cancer; 2024 Sep; 24(1):1206. PubMed ID: 39350057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype.
    Owonikoko TK; Dwivedi B; Chen Z; Zhang C; Barwick B; Ernani V; Zhang G; Gilbert-Ross M; Carlisle J; Khuri FR; Curran WJ; Ivanov AA; Fu H; Lonial S; Ramalingam SS; Sun SY; Waller EK; Sica GL
    J Thorac Oncol; 2021 Mar; 16(3):464-476. PubMed ID: 33248321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity.
    Redin E; Quintanal-Villalonga Á; Rudin CM
    Trends Cancer; 2024 Oct; 10(10):935-946. PubMed ID: 39164163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive biomarkers for immunotherapy response in extensive-stage SCLC.
    Zhu L; Qin J
    J Cancer Res Clin Oncol; 2024 Jan; 150(1):22. PubMed ID: 38245636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transitioning to a Personalized Approach in Molecularly Subtyped Small-Cell Lung Cancer (SCLC).
    Grenda A; Krawczyk P; Obara A; Gajek Ł; Łomża-Łaba A; Milanowski J
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ASCL1 regulates super-enhancer-associated miRNAs to define molecular subtypes of small cell lung cancer.
    Miyakawa K; Miyashita N; Horie M; Terasaki Y; Tanaka H; Urushiyama H; Fukuda K; Okabe Y; Ishii T; Kuwahara N; Suzuki HI; Nagase T; Saito A
    Cancer Sci; 2022 Nov; 113(11):3932-3946. PubMed ID: 35789143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transcriptomic Heterogeneity of EGFR-Mutant Non-Small Cell Lung Cancer Evolution Toward Small-Cell Lung Cancer.
    Oh S; Koh J; Kim TM; Kim S; Youk J; Kim M; Keam B; Jeon YK; Ku JL; Kim DW; Chung DH; Heo DS
    Clin Cancer Res; 2024 Oct; 30(20):4729-4742. PubMed ID: 39150541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.